HUE063528T2 - Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére - Google Patents

Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére

Info

Publication number
HUE063528T2
HUE063528T2 HUE16763663A HUE16763663A HUE063528T2 HU E063528 T2 HUE063528 T2 HU E063528T2 HU E16763663 A HUE16763663 A HU E16763663A HU E16763663 A HUE16763663 A HU E16763663A HU E063528 T2 HUE063528 T2 HU E063528T2
Authority
HU
Hungary
Prior art keywords
antibodies
treatment
lupus nephritis
nephritis
lupus
Prior art date
Application number
HUE16763663A
Other languages
English (en)
Hungarian (hu)
Inventor
Scott Ronald Brodeur
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HUE063528T2 publication Critical patent/HUE063528T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE16763663A 2015-09-01 2016-08-31 Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére HUE063528T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562212810P 2015-09-01 2015-09-01
US201562257336P 2015-11-19 2015-11-19
US201662287587P 2016-01-27 2016-01-27

Publications (1)

Publication Number Publication Date
HUE063528T2 true HUE063528T2 (hu) 2024-01-28

Family

ID=56896810

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16763663A HUE063528T2 (hu) 2015-09-01 2016-08-31 Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére

Country Status (16)

Country Link
US (3) US20170058038A1 (enExample)
EP (1) EP3344655B1 (enExample)
JP (2) JP2018529661A (enExample)
KR (1) KR20180039172A (enExample)
CN (1) CN107922501A (enExample)
AU (1) AU2016317028B2 (enExample)
BR (1) BR112018001907A2 (enExample)
CA (1) CA2993996A1 (enExample)
CL (1) CL2018000317A1 (enExample)
DK (1) DK3344655T5 (enExample)
ES (1) ES2969968T3 (enExample)
HU (1) HUE063528T2 (enExample)
MX (1) MX390653B (enExample)
PH (1) PH12018500445B1 (enExample)
PL (1) PL3344655T3 (enExample)
WO (1) WO2017040566A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
MX2019013132A (es) * 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
WO2020006347A1 (en) * 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
KR20210097750A (ko) * 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
RU2006141632A (ru) * 2004-04-27 2008-06-10 Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) Антагонистические моноклональные анти-cd40-антитела и способы их применения
JP5027804B2 (ja) * 2005-05-26 2012-09-19 シアトル ジェネティクス，インコーポレーテッド ヒト化抗ｃｄ４０抗体およびその使用方法
SMP200800064B (it) * 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
EP2796467B1 (en) * 2010-03-31 2018-03-28 Boehringer Ingelheim International GmbH Anti-CD40 antibodies
KR102037432B1 (ko) * 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
PH12018500445A1 (en) 2018-09-10
JP2021185169A (ja) 2021-12-09
ES2969968T3 (es) 2024-05-23
EP3344655A1 (en) 2018-07-11
US20170058038A1 (en) 2017-03-02
JP2018529661A (ja) 2018-10-11
AU2016317028A1 (en) 2018-02-22
DK3344655T5 (da) 2024-10-07
AU2016317028B2 (en) 2021-09-09
MX390653B (es) 2025-03-21
PH12018500445B1 (en) 2022-08-10
US20230265203A1 (en) 2023-08-24
EP3344655B1 (en) 2023-07-26
KR20180039172A (ko) 2018-04-17
WO2017040566A1 (en) 2017-03-09
CL2018000317A1 (es) 2018-07-20
BR112018001907A2 (pt) 2018-09-25
PL3344655T3 (pl) 2024-02-19
MX2018002447A (es) 2018-06-15
US20190177420A1 (en) 2019-06-13
CA2993996A1 (en) 2017-03-09
CN107922501A (zh) 2018-04-17
DK3344655T3 (da) 2023-10-09

Similar Documents

Publication Publication Date Title
IL251970B (en) Anti-cd79b antibodies and methods of use
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3851537T5 (da) Behandling af hyperbilirubinæmi
HUE048284T2 (hu) Anti-CD40 antitestek és alkalmazásuk
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
SG10201912085WA (en) Anti-cd33 antibodies and methods of use thereof
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
PT3215532T (pt) Anticorpos anti-tim3 e métodos de utilização
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3110843T3 (da) Kombinationsterapier med anti-cd38-antistoffer
HUE063044T2 (hu) Anti-CD38 ellenanyagok akut limfoblasztos leukémia kezelésére
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
IL252929B (en) Anti-acth antibodies from humans and their use
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
BR112016022976A2 (pt) Métodos para o tratamento de hcv
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3344655T3 (da) Brug af anti-cd40-antistoffer til behandling af lupus nefritis